Radium 223 was introduced for metastatic castration-resistant prostate cancer based on the results of a randomized controlled trial showing risk reduction for death and skeletal events. Our aim was to evaluate the outcome of patients receiving radium 223 in a real-world setting.
Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region
Alongi, Filippo;
2018-01-01
Abstract
Radium 223 was introduced for metastatic castration-resistant prostate cancer based on the results of a randomized controlled trial showing risk reduction for death and skeletal events. Our aim was to evaluate the outcome of patients receiving radium 223 in a real-world setting.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Maruzzo Xofigo Triveneto (paper).pdf
gestori archivio
Tipologia:
Full Text
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
639.52 kB
Formato
Adobe PDF
|
639.52 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
